摘要
本文报道了用抗体捕获ELISA检测抗HBcIgA临床应用的初步结果。在检测抗HBcIgA的148份临床血清标本中,58份急性乙肝、32份慢性活肝、9份肝硬化和8份重肝、亚重肝及肝癌的抗HBcIgA阳性率分别为62.1%、63.6%、66.0%和100.0%;9例慢迁肝和32例无症状携带者的阳性率分别为22.2%和0.0%;正常对照组(98例健康献血员)无一例阳性。结果提示:抗HBcIgA与肝细胞损伤程度相关,是临床诊疗和预后判断的有价值的指标。表明本试剂盒具有良好的适用性和可用性。
A methoa of ACST-ELISA for the aetection ot anti-HBc IgA class in serum and its clinical significance was introduced. Among 143 samples tested, positive rate were found to be 62.1%, 63.6%, 66.0%, 100.0%, 22.2% and 0.0%, respectively in 58 cases of acute hepatitis B, 32 cases of chronic active hepatitis B, 9 cases of cirrhosis hepatitis B,8 cases of fulminant hepatitis B, fulminant subacute hepatitis B, liver cancer, 9 cases of chronic persistant hepatitis and 32 cases of assymptomatic carriers. None was found to be positive in 98 cases without hepatitis. From this result it is seemed that Anti-HBc IgA in serum might be as if suggested of hepatic cellular damage in hepatitis B. Its detection might be helpful in the diagnosis of the disease and it prognosis as well. We recommended that the method of ACST-ELISA was good for use.
出处
《免疫学杂志》
CAS
CSCD
北大核心
1990年第4期272-274,共3页
Immunological Journal